Peptide News Digest

Novo International Wegovy Pill 2M+ US Scripts, BriaCell Bria-OVA+ Ovarian, Tsinghua NK2R Peptide Design Competition, Aivocode CAQK, Fibulin-4 Breast Cancer Peptide

Novo international Wegovy pill expansion as US scripts cross 2M, BriaCell Bria-OVA+ ovarian pipeline, Tsinghua NK2R AI competition, Aivocode CAQK, Fibulin-4.

10 stories · Covering industry, clinical-trials, research, regulatory

Editor's Note

Monday digest centered on the CNBC May 18 piece in which Novo Nordisk's Executive Vice President for International Operations Emil Kongshøj Larsen signaled the company is 'all in' on launching Wegovy pill outside the US — UK, Germany, and Denmark sit at the front of the queue — while disclosing that cumulative US Wegovy pill prescriptions have crossed 2 million in the 18 weeks since the January 5 launch. The 2M+ milestone roughly doubles the May 14 figure of >1M cumulative US users that CEO Doustdar shared. CNBC also surfaced a fresh framing from both companies: Foundayo and Wegovy pill are now positioned as targeting different patient segments rather than competing head-to-head — Wegovy pill is 'injectable-like efficacy' in oral form, Foundayo is a 'starter GLP-1' with no fasting requirement and a small-molecule manufacturing path. On the non-GLP-1 side, BriaCell expanded its pipeline May 15 with Bria-OVA+ for ovarian cancer (ATCC cell-line license), completed Bria-PROS+ clinical manufacturing for prostate cancer May 14, and added Penn Medicine's Abramson Cancer Center to its Phase 3 Bria-IMT breast cancer trial May 13. Tsinghua University's Beijing Frontier Research Center for Biological Structure ran an international Peptide Design Competition with about 300 participants targeting NK2R, a metabolic-regulation and appetite receptor, as a benchmark exercise for AI-driven peptide drug design. Two non-GLP-1 research items round out the cycle: Aivocode is preparing first-in-human dosing for its CAQK brain-injury tetrapeptide on the December 2025 EMBO Molecular Medicine preclinical baseline, and a 2026 Molecular Therapy Oncology paper reported a Fibulin-4-targeting peptide selectively killed metastatic breast cancer cells in mice. The PCAC public-comment window for the July 23-24 meeting now has firm dates: written submissions close July 9, oral presentation requests close June 30.

Industry

Novo Nordisk International Wegovy Pill Expansion: EVP Larsen 'All In' on UK, Germany, Denmark Following 2M+ US Prescription Milestone

Novo Nordisk's Executive Vice President for International Operations Emil Kongshøj Larsen told CNBC May 18 the company is preparing to go 'all in' on launching its Wegovy pill outside the US, with UK, Germany, and Denmark at the front of the international queue. The company disclosed cumulative US Wegovy pill prescriptions have crossed 2 million in the 18 weeks since the January 5 launch — roughly double the >1M figure CEO Maziar Doustdar shared on May 14. Larsen's quote: 'When we launch, we'll go all in.' The international expansion lands as Novo's full-year 2026 guidance still calls for revenue and profit declines between 4% and 12%, but the company hiked guidance slightly last week after Q1 oral semaglutide sales beat expectations. The international Wegovy pill timing matters for Lilly's Foundayo (orforglipron), which had its US PBM coverage activate mid-May but has no near-term international launch date.

#novo-nordisk #wegovy-pill #international-launch #oral-semaglutide #cnbc #foundayo #competition
Clinical Trials

BriaCell Pipeline Expansion to Ovarian Cancer (May 15): Bria-OVA+ Personalized Off-the-Shelf Cell-Based Immunotherapy, ATCC Cell-Line Licensing

BriaCell announced May 15 it has expanded its pipeline to include Bria-OVA+, a next-generation personalized off-the-shelf cell-based immunotherapy for ovarian cancer. The company licensed ovarian-cancer cell lines from American Type Culture Collection (ATCC) and has commenced development activities to support production of Bria-OVA+ for potential clinical use. The candidate is designed with additional immune-stimulating components to support enhanced anti-tumor activity, building on Phase 2 efficacy and tolerability data in metastatic breast cancer. The company is targeting ovarian cancer because an estimated 21,010 women in the US will be diagnosed in 2026 and approximately 12,450 will die from the disease, with ovarian cancer remaining the deadliest gynecologic cancer. The expansion adds to the BriaCell platform spanning Bria-IMT (metastatic breast), Bria-OTS+ (next-gen breast and prostate), Bria-PROS+ (prostate), and Bria-BRES+ (breast).

#briacell #bria-ova-plus #ovarian-cancer #cell-based-immunotherapy #atcc #personalized-immunotherapy #gynecologic-cancer
Clinical Trials

BriaCell Bria-PROS+ Clinical Manufacturing Completed for Prostate Cancer (May 14) — Penn Medicine Abramson Added to Phase 3 Bria-IMT Breast Cancer Trial (May 13)

BriaCell announced May 14 it has completed manufacturing of clinical supplies for Bria-PROS+, the company's prostate cancer cell-based immunotherapy candidate, positioning the program for an IND filing and Phase 1/2 initiation later in 2026. On May 13, BriaCell added Penn Medicine's Abramson Cancer Center as a clinical site for the pivotal Phase 3 Bria-IMT metastatic breast cancer study, bringing the trial-site network to include Smilow Cancer Hospital at Yale New Haven and Los Angeles Cancer Network. The two announcements come ahead of BriaCell's six accepted ASCO 2026 abstract presentations on Bria-IMT and Bria-OTS+ in metastatic breast cancer, scheduled for the May 29-June 2 Chicago meeting. The May 6 FDA clearance for the Bria-BRES+ clinical study completes a busy two-week operational cadence for the company.

#briacell #bria-pros-plus #bria-imt #prostate-cancer #metastatic-breast-cancer #phase-3 #penn-medicine #abramson-cancer-center
Research

Tsinghua FRCBS Peptide Design Competition: 300 Researchers Use AI to Target NK2R Receptor for Obesity, Diabetes, and Metabolic Disease

Beijing Frontier Research Center for Biological Structure (FRCBS) at Tsinghua University organized an international Peptide Design Competition this year with about 300 participants from around the world designing peptide candidates targeting NK2R — a G-protein-coupled receptor involved in energy metabolism and appetite regulation. The competition is structured as a benchmarking exercise to test how well AI-driven structural predictions hold up under experimental scrutiny, with participants submitting designs that are then synthesized and tested for binding and functional activity. NK2R is a target of growing interest in the obesity-pharmacology field as the GLP-1 receptor space saturates and pharmaceutical R&D groups look for the next-generation metabolic-disease receptor that could complement GLP-1/GIP/glucagon agonism. The framework — AI design followed by wet-lab validation — is positioned as a community blueprint for de novo peptide discovery at large.

#tsinghua #frcbs #peptide-design-competition #nk2r #ai-drug-design #metabolic-receptor #de-novo-peptide-design
Regulatory

PCAC July 23-24 Public Comment Window Set: Written Submissions Close July 9, Oral Presentation Requests Close June 30

The Pharmacy Compounding Advisory Committee meeting on July 23-24, 2026 — at which seven peptides (BPC-157, KPV, TB-500, MOTs-C on Day 1; Emideltide/DSIP, Semax, Epitalon on Day 2) will be discussed for 503A compounding inclusion — now has firm public-comment deadlines. Written submissions are due July 9, 2026 via regulations.gov; oral presentation requests close June 30, with the FDA allocating presentation slots after review. The PCAC review follows the April 23, 2026 effective date when 12 peptides came off the FDA's Category 2 bulks list. Industry stakeholders, patient groups, and clinicians are organizing through the SSRPi network and the Alliance for Pharmacy Compounding to coordinate testimony. The combined regulatory cycle — PCAC plus the parallel April 30 503B bulks-list proposal closing June 29 — will reshape the compounding-pharmacy economy through 2027 and determine which research peptides remain accessible through licensed channels.

#pcac #fda #503a-compounding #bpc-157 #kpv #tb-500 #public-comment #bulks-list
Clinical Trials

Aivocode CAQK Brain-Injury Tetrapeptide Phase 1 Preparation Following December 2025 EMBO Molecular Medicine Baseline

Aivocode is preparing first-in-human Phase 1 dosing for its CAQK tetrapeptide candidate in acute traumatic brain injury, building on the December 2025 EMBO Molecular Medicine paper that established the neuroprotective mechanism in rodent models. CAQK is a four-amino-acid peptide (Cys-Ala-Gln-Lys) that homes specifically to brain extracellular matrix exposed by tissue damage, enabling targeted delivery of therapeutic payloads to injured but not healthy brain regions. The preclinical data showed reduced lesion volume and improved functional recovery in mouse and rat TBI models when CAQK was conjugated to neuroprotective small molecules. The Phase 1 program — IND-enabling work ongoing — would represent one of the few peptide-based TBI candidates entering clinical testing, an indication with no FDA-approved neuroprotective therapies.

#aivocode #caqk #traumatic-brain-injury #tetrapeptide #embo-molecular-medicine #neuroprotection #phase-1-prep
Research

BPC-157 Multifunctionality Comment Paper in Pharmaceuticals: Angiogenesis and Nitric Oxide Pathway Discussion Continues Ahead of PCAC

A 2026 Pharmaceuticals (MDPI) comment paper responds to the Józwiak et al. 2025 multifunctionality review of BPC-157, focusing on the peptide's role in targeting angiogenesis and modulating nitric oxide's cytotoxic versus protective actions. The response paper argues BPC-157's clinical claim breadth — wound healing, GI ulcer repair, tendon healing, neuroprotection — derives from a single biochemical hub: the peptide's interaction with vascular endothelial growth factor receptor 2 (VEGFR2) signaling and the NO/cGMP axis. The discussion lands as BPC-157 sits on the FDA's bulks-list review track for the July 23-24 PCAC meeting, with the underlying mechanistic literature still anchored on a small number of research groups. The Pharmaceuticals exchange illustrates the pre-clinical evidence gap that PCAC will weigh against the wide compounding-pharmacy demand signal.

#bpc-157 #pharmaceuticals-journal #angiogenesis #nitric-oxide #vegfr2 #mechanism #pcac
Research

Molecular Therapy Oncology 2026: Fibulin-4-Targeting Peptide Selectively Killed Metastatic Breast Cancer Cells in Mouse Models

A Molecular Therapy Oncology 2026 paper from a multi-institution collaboration reported that a peptide engineered against Fibulin-4 — a glycoprotein overexpressed in metastatic breast cancer extracellular matrix — successfully targeted and killed metastatic breast cancer cells in mice. The same peptide doubles as an imaging probe, supporting peptide-based detection alongside therapy. The Fibulin-4 target is significant because metastatic breast cancer remains the leading cause of breast cancer mortality and current targeted therapies (HER2, hormone-receptor) leave a substantial therapy gap for triple-negative metastatic disease. The work joins the broader peptide-drug-conjugate field in which six PDCs are in Phase 3 trials and roughly 96 are in development, even as only Lutathera holds active FDA approval after the 2024 Pepaxto withdrawal.

#fibulin-4 #metastatic-breast-cancer #molecular-therapy-oncology #peptide-drug-conjugate #imaging-probe #tumor-targeting-peptide
Industry

Foundayo and Wegovy Pill Differentiation: 'Injectable-Like Efficacy' vs 'Starter GLP-1' Positioning Per Novo and Lilly Commentary

The CNBC May 18 piece surfaced explicit company-supported positioning that Foundayo (orforglipron) and oral Wegovy are targeting different patient segments rather than competing head-to-head. Novo's framing for Wegovy pill is 'injectable-like efficacy' in oral form, with the Phase 3 OASIS-MAINTAIN data anchoring approximately 15% mean weight loss. Lilly's framing for Foundayo positions it as more of a 'starter' GLP-1 — lower weight-loss ceiling (around 11.2% in ATTAIN-1) but no food-or-water dosing restrictions and a non-peptide small-molecule manufacturing path that supports a lower long-term price. Both companies say the pills are expanding the market rather than significantly cannibalizing demand for the injectables — a different framing than the 'oral-disrupts-injectable' narrative that dominated 2025 coverage. The market-expansion hypothesis will be testable as ADA 2026 (June 5-8) and Q2 2026 earnings prints land.

#foundayo #wegovy-pill #oral-glp-1 #positioning #orforglipron #oral-semaglutide #market-expansion
Research

Chemical Communications (RSC) 2026: Generative AI Peptide Drug Design Review Frames the Methods Wave Behind the NK2R Competition and the GLP-1 De Novo Programs

A Chemical Communications (Royal Society of Chemistry) 2026 review on peptide-based drug design using generative AI synthesizes the methods landscape behind the wave of community competitions and pharmaceutical-industry de novo programs that landed in 2026. The review covers ProteoGPT and related protein-language-model architectures, AlphaFold3-based pose prediction, diffusion-model peptide structure generation, and the experimental-validation cycle that turns AI designs into bench-tested candidates. It frames the Tsinghua FRCBS NK2R Peptide Design Competition and the published ultra-long-acting GLP-1 receptor agonist de novo design work as proof-points that the AI-design stack has crossed the threshold from generative novelty to drug-discovery utility. The piece lands as the AI/peptide field tracks toward routine kilogram-scale syntheses (enlicitide PCSK9, others) and into Phase 1/2 candidates inside roughly 18 months from in silico design.

#chemical-communications #generative-ai #peptide-drug-design #alphafold3 #protein-language-models #ai-discovery #review-article